Holen Sie sich die Stockscreener-App
106.24
3.00%
-3.29
Schlusskurs vom Vortag:
$109.53
Offen:
$108.47
24-Stunden-Volumen:
2.43M
Relative Volume:
0.85
Marktkapitalisierung:
$23.03B
Einnahmen:
$819.56M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-18.50
EPS:
-5.7434
Netto-Cashflow:
$-951.64M
1W Leistung:
-2.66%
1M Leistung:
-26.47%
6M Leistung:
-46.55%
1J Leistung:
+60.58%
1-Tages-Spanne:
$106.20
$110.83
1-Wochen-Bereich:
$104.48
$110.95
52-Wochen-Spanne:
$65.56
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
106.24 | 23.74B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insider Sell Alert: Michael Smith Sells 6,149 Shares of Insmed I - GuruFocus
Insmed chief legal officer Michael Smith sells $666,982 in shares - Investing.com
Insmed (INSM) slides 3% as investors weigh recent shelf registration and post-earnings reset - Quiver Quantitative
Insmed Insider Sold Shares Worth $666,982, According to a Recent SEC Filing - Moomoo
Insmed (INSM) legal chief sells 6,149 shares under Rule 10b5-1 plan - Stock Titan
Insmed CEO defends BRINSUPRI launch as sales surge, TPIP pipeline gains focus - MSN
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
TD Cowen Initiates Insmed(INSM.US) With Buy Rating, Announces Target Price $243 - Moomoo
Competitive Pressures Prompt Truist to Cut Target on Insmed (INSM) - Insider Monkey
INSM, FSLR, APTV: Dreaded death cross has formed on these stocks — what it means for investors - MSN
11 Best Long Term US Stocks to Buy Right Now - Insider Monkey
Assessing Insmed (INSM) Valuation After Recent Share Price Pullback And Strong Multi Year Returns - Yahoo Finance
Insmed's Q1 earnings beat, sales miss estimates, stock tanks 23% - MSN
William Blair Maintains Insmed(INSM.US) With Buy Rating - Moomoo
Analyst Reaffirms Buy on Insmed, Citing Strong ENCORE Phase IIIb Arikayce Data and TPIP IPF Upside - TipRanks
William Lewis lists proposed INSM share sales (05/2026) — INSM - Stock Titan
Insmed To Present at March 2026 Investor Conferences - GuruFocus
UBS Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $166 - Moomoo
Insmed, Inc. $INSM Shares Purchased by iA Global Asset Management Inc. - MarketBeat
Insmed Incorporated (INSM): Investor Outlook Reveals 84% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus - sharewise.com
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
AustralianSuper Pty Ltd Takes $1.74 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed CFO Sara Bonstein sells $961k in company stock - Investing.com UK
Insmed Inc files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Insmed Inc Files For Mixed Shelf Offering Size Not DisclosedSEC Filing - TradingView
Insmed (NASDAQ: INSM) files shelf registration to enable future stock and debt offers - Stock Titan
Darwin Global, affiliates hold 7.8% of INSMED (INSM) in 13G/A filing - Stock Titan
Insmed CFO Sara Bonstein sells $961k in company stock By Investing.com - Investing.com South Africa
Insmed Insiders Sold Shares Worth Over $3.2M - TradingView
Insmed (NASDAQ: INSM) director awarded 3,305 RSUs, now holds 246,081 shares - Stock Titan
Insmed (INSM) CFO sells 8,272 shares to cover RSU tax obligations - Stock Titan
Insmed (INSM) director Carol Schafer awarded 3,305 RSUs in equity grant - Stock Titan
INSMED (INSM) COO Roger Adsett sells 5,837 shares to cover RSU taxes - Stock Titan
Insmed (INSM) director granted 3,305 RSUs vesting after one year - Stock Titan
Insmed (NASDAQ: INSM) CMO sells 18,333 shares under Rule 10b5-1 plan - Stock Titan
Insmed (INSM) legal chief sells 4,109 shares to cover RSU taxes - Stock Titan
INSMED Inc (INSM) director Brennan receives 3,305 RSUs and reports 124,238 total shares - Stock Titan
Insmed (NASDAQ: INSM) director receives 3,305 RSUs equity award - Stock Titan
Director Leo Lee (NASDAQ: INSM) receives 3,305 RSUs equity grant - Stock Titan
INSMED (INSM) CEO Lewis sells 13,283 shares to cover RSU tax obligations - Stock Titan
Insmed (NASDAQ: INSM) investors approve board picks, pay and auditor - Stock Titan
NYLI Fiera SMID Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
INSM Maintained by Truist Securities -- Price Target Lowered to $185 - GuruFocus
[144] INSMED Inc SEC Filing - Stock Titan
Insmed stock (US4576693075): Truist cuts price target to $185 on competitive risks - AD HOC NEWS
Truist Financial Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $185 - Moomoo
Insmed | 4: Statement of changes in beneficial ownership of securities-Officer Flammer Martina M.D. - Moomoo
Truist cuts Insmed stock price target to $185 on competitive risks - Investing.com UK
Insmed chief medical officer Flammer sells $1.3 million in shares By Investing.com - Investing.com South Africa
Insmed | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
2.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):